D2B3

D2B3 is developing a proprietary monoclonal antibody, D2B3-01, that temporarily opens the blood-brain barrier (BBB) to allow therapeutic agents (including small molecules, peptides, proteins, and oligonucleotides) to reach the brain, then reseals within hours. The venture tackles a fundamental obstacle in neurology and

Based, D2B3 works in neuro.

Profile

D2B3 is developing a proprietary monoclonal antibody, D2B3-01, that temporarily opens the blood-brain barrier (BBB) to allow therapeutic agents (including small molecules, peptides, proteins, and oligonucleotides) to reach the brain, then reseals within hours. The venture tackles a fundamental obstacle in neurology and neuro-oncology: over 98% of drugs cannot cross the BBB, which slows development, […]

Its activity falls under neuro; the profile below is assembled from public directory data.

The company is listed at the Creative Destruction Lab alumni company stage of development.

Website: d2b3.bio